Octagon Capital Advisors Exits Xilio Therapeutics Stake

TL;DR

**Octagon Capital Advisors LP just dumped all its Xilio Therapeutics shares.**

AI Summary

Octagon Capital Advisors LP, a Delaware-based investment firm, filed an Amendment No. 2 to its Schedule 13G on February 6, 2024, indicating a significant change in its beneficial ownership of Xilio Therapeutics, Inc. common stock. As of January 2, 2024, Octagon Capital Advisors LP reported having 0 sole voting power, 0 shared voting power, 0 sole dispositive power, and 0 shared dispositive power over Xilio Therapeutics shares. This filing suggests that Octagon Capital Advisors LP has either sold off its entire stake or no longer holds a reportable beneficial ownership in Xilio Therapeutics, which could signal a lack of confidence from a previous institutional investor.

Why It Matters

This matters because a major institutional investor, Octagon Capital Advisors LP, has reduced its beneficial ownership in Xilio Therapeutics to zero, potentially signaling a loss of confidence in the company's future prospects.

Risk Assessment

Risk Level: medium — The complete divestment by an institutional investor like Octagon Capital Advisors LP could indicate underlying concerns about Xilio Therapeutics, posing a medium risk to current and prospective shareholders.

Analyst Insight

A smart investor would view this divestment by Octagon Capital Advisors LP as a potential red flag and conduct further due diligence into Xilio Therapeutics' financials and future prospects before making any investment decisions.

Key Numbers

• 0 — Sole Voting Power (Indicates Octagon Capital Advisors LP no longer holds any shares with sole voting rights in Xilio Therapeutics.)
• 0 — Shared Voting Power (Shows Octagon Capital Advisors LP no longer shares voting rights over any Xilio Therapeutics shares.)
• 0 — Sole Dispositive Power (Means Octagon Capital Advisors LP cannot independently sell any Xilio Therapeutics shares.)
• 0 — Shared Dispositive Power (Implies Octagon Capital Advisors LP no longer has shared control over selling Xilio Therapeutics shares.)

Key Players & Entities

• Octagon Capital Advisors LP (company) — reporting person, previously held shares in Xilio Therapeutics, Inc.
• Xilio Therapeutics, Inc. (company) — subject company whose common stock is being reported on
• Delaware (company) — place of organization for Octagon Capital Advisors LP
• 0 (dollar_amount) — number of shares with sole voting power, shared voting power, sole dispositive power, and shared dispositive power
• January 2, 2024 (date) — date of event which requires filing of this statement

Forward-Looking Statements

• Xilio Therapeutics' stock price may experience downward pressure due to the institutional divestment. (Xilio Therapeutics, Inc.) — medium confidence, target: Q1 2024
• Other institutional investors might re-evaluate their positions in Xilio Therapeutics following this filing. (Institutional Investors) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securiti

Filing Documents

• j21244sc13ga2.htm (SC 13G/A) — 60KB
• 0001214659-24-002001.txt ( ) — 62KB

(a)

Item 1(a). Name of Issuer: XILIO THERAPEUTICS, INC.

(b)

Item 1(b). Address of Issuer's Principal Executive Offices: 828 Winter Street Suite 300, Waltham, MA 02451

(a)

Item 2(a). Name of Person Filing: This statement is being jointly filed by: • Octagon Capital Advisors LP, a Delaware limited partnership, (“Octagon”) • Octagon Investments Master Fund LP, an exempted limited partnership established in the Cayman Islands ("Master Fund") • Ting Jia, as the principal beneficial owner of Octagon (“Mr. Jia”). Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Octagon serves as the investment manager of the Master Fund. Mr. Jia is the managing member of Octagon. By virtue of these relationships, each of Octagon and Mr. Jia may be deemed to beneficially own the Issuer’s Common Shares directly owned by the Master Fund.

(b)

Item 2(b). Address of Principal Business Office or, if none, Residence: 645 Madison Avenue 21 st Floor, New York, NY 10065

(c)

Item 2(c). Citizenship: USA

(d)

Item 2(d). Title of Class of Securities: Common Stock, $0.0001 Par Value ("Common Shares" or "Shares")

(e)

Item 2(e). CUSIP Number: 98422T100 Item 3. If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) ¨ Broker or dealer registered under Section 15 of the Act; (b) ¨ Bank as defined in Section 3(a)(6) of the Act; (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act; (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940; (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E) ; (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F) ; (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G) ; (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; (j) ¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J) ; (k) ¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K) . If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 0; (b) Percent of Class: 0% The percentage reported on this Schedule 13G, 0%, based on 27,542,000 shares of common stock outstanding as of November 7, 2023, as reported in the Form 10-Q filed by the issuer on November 9, 2023. (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: (iv) shared power to dispose or to direct the d

View Full Filing

View this SC 13G/A filing on SEC EDGAR